NP90219b Leuprorelin (Prostap®)
A Modification Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)
- Source
- Find a Tender
- Type
- Contract (Supply)
- Duration
- 5 year
- Value
- £2M-£2M
- Sector
- HEALTH
- Published
- 05 Dec 2024
- Delivery
- To 05 Dec 2029 (est.)
- Deadline
- n/a
Concepts
Location
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014
2 buyers
- NHS National Services Scotland NSS Edinburgh
1 supplier
- Takeda London
Description
The Framework Agreement is for the supply of Leuprorelin (Prostap®) to NHS Scotland. The Framework Agreement has been awarded as a single supplier framework agreement to one (1) Framework Participants. The Framework Participant is required to supply Goods to the designated delivery points throughout Scotland for use by Participating Authorities.
Ammendments to Previous Notice
2. Contract value
GBP 2,011,890 2,117,273
Award Detail
| 1 | Takeda (London)
|
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Contract modified due to unforeseen circumstances.
Legal Justification
This modification is necessary to meet the additional demands of the Scottish Health and Social Care sector to maintain necessary supply due to circumstances unforeseen by the Authority, and at this time have rendered this modification necessary, in line with Regulation 72(1)(b) of the Public Contracts (Scotland) Regulations 2015.
Other Information
The estimated value of the Framework Agreement referred to in Section V.2.4 covers the twenty four (24) month contract duration and the thirty six (36) month extension period of the Framework Agreement. (SC Ref:784398)
Reference
- FTS 039327-2024